An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of Levetiracetam (LEV) used as
monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in
the LEV 1000 mg/day to 2000 mg/day group, in newly or recently diagnosed epilepsy subjects.